Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
Mouse, Rat (at least 90% immunogen sequence identity)
ICC (1:100 - 1:1000)
Western blot (1:500 - 1:3000)
Specificity and Use
CBFA2T2 / MTGR1 antibody was raised against recombinant fragment corresponding to a region within amino acids 401 and 604 of CBFA2T2 (SwissProt O43439). Percent identity by BLAST analysis: Human (100%); Mouse, Rat (95%); Chicken (80%).
0.1 M Tris-glycine, pH 7.0, 10% glycerol, 0.01% Thimerosal
Keep as concentrated solution. Aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
CBFA2T2 Antibody, Brain mtgr1 mrna, partial 5' Antibody, EHT Antibody, ETO homolog on chromosome 20 Antibody, MTGR1 Antibody, p85 Antibody, MTG8-like protein Antibody, MTG8-related protein 1 Antibody, Translocated to, 2 Antibody, Protein CBFA2T2 Antibody, ZMYND3 Antibody
In acute myeloid leukemia, especially in the M2 subtype, the t(8;21)(q22;q22) translocation is one of the most frequent karyotypic abnormalities. The translocation produces a chimeric gene made up of the 5'-region of the RUNX1 (AML1) gene fused to the 3'-region of the CBFA2T1 (MTG8) gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.